Search clinical trials for: florbetapir F 18

Total 2006 results

Brigham and Women's Hospital

Terminated

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

Cardiac Amyloidosis

United States
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Progressive Cognitive Decline

United States
Avid Radiopharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...

Completed

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

Parkinson's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Physician Training Methods to Read Florbetapir-PET Scans

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment
Avid Radiopharmaceuticals

Completed

Evaluation of PET Scan Timing Relative to AV-45 Injection Time

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Healthy Volunteers

Alzheimer Disease

United States
Chang Gung Memorial Hospital

Unknown

Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination (PMPBB3/AV45)

Alzheimer's Disease

Taiwan
Avid Radiopharmaceuticals

Completed

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Reader Training Processes

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

Alzheimer's Disease

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
Eli Lilly and Company

Active, not recruiting

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD) (GERAS-US)

Alzheimer Disease | Mild Cognitive Impairment

United States
The Cleveland Clinic
Avid Radiopharmaceuticals

Terminated

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Cardiac Amyloidosis

United States
Mayo Clinic

Completed

Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

Amyloidosis

United States
Avid Radiopharmaceuticals
Eli Lilly and Company; PRA Health Sciences

Completed

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials (RAmP)

Alzheimer Disease | Cognition Disorders

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Alzheimer's Disease

France, Italy, United States
University of California, San Francisco
Avid Radiopharmaceuticals; Alzheimer's Drug Discovery Foundation

Recruiting

Effects of Brain Beta-Amyloid on Postoperative Cognition

Postoperative Cognitive Dysfunction

United States
Avid Radiopharmaceuticals
General Electric; American College of Radiology Imaging Network

Completed

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Northwestern University

Completed

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia (PPA)

Dementia | Alzheimer Disease | Primary Progressive Aphasia

United States
Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
Eli Lilly and Company

Completed

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

Alzheimer Disease

United States, Japan, United Kingdom
University Hospital, Toulouse
Institut National de la Santé Et de la Recherche Médicale, France; Avid Radiopharmaceuticals

Completed

Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage (COGHIC-AV45)

Intracerebral Hemorrhage

France
Brigham and Women's Hospital
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaborators

Recruiting

Molecular Imaging of Primary Amyloid Cardiomyopathy (MICA)

Cardiomyopathy | Amyloidosis, Primary

United States
Avid Radiopharmaceuticals

Completed

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Avid Radiopharmaceuticals

Completed

Florbetapir Calibration to the Centiloid Scale

Alzheimer's Disease

United States, Australia
Avid Radiopharmaceuticals

Completed

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects (MCI)

Alzheimer's Disease

United States
Mayo Clinic
Yale University; Columbia University; National Institute on Aging (NIA); Brigham... and other collaborators

Completed

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS) (KEEPS)

Alzheimer Dementia

United States
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Completed

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

Mild Cognitive Impairment (MCI) | Alzheimer's Disease (AD) | Significant Memory Concern (SMC) | Early Mild Cognitive Impairment (EMCI) | Late Mild Cognitive Impairment (LMCI)

United States, Canada
Avid Radiopharmaceuticals

Completed

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

Frontotemporal Dementia | Alzheimer's Disease

United Kingdom
Assistance Publique - Hôpitaux de Paris

Completed

Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging (AVILL)

Alzheimer Disease

France
Chang Gung Memorial Hospital

Completed

Novel Neuroimage Study in Tauopathies With Parkinsonism

Parkinsonism

Taiwan
Chang Gung Memorial Hospital

Completed

18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls

Frontotemporal Dementia | Progressive Supranuclear Palsy | Alzheimer's Disease | Vascular Cognitive Impairment | Cortical Basal Syndrome

Taiwan
Siemens Molecular Imaging
Fudan University

Completed

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

Head and Neck Cancer | Lung Cancer | Liver Cancer

China
John M. Buatti
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

Uterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus Neoplasms

United States
Siemens Molecular Imaging

Completed

Exploratory and Safety Study of [F-18]W372

Alzheimer's Disease

United States
ABX advanced biochemical compounds GmbH

Completed

F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

Prostate Cancer | Prostate Cancer Recurrent

France
Siemens Molecular Imaging

Completed

A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation (FLT101)

Head and Neck Cancer | Lung Cancer

United States
Northwell Health

Completed

Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

Neuroendocrine Tumors

United States

Search clinical trials for: florbetapir F 18

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations